BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 22782963)

  • 21. Selective bladder preservation by combination treatment of invasive bladder cancer.
    Kaufman DS; Shipley WU; Griffin PP; Heney NM; Althausen AF; Efird JT
    N Engl J Med; 1993 Nov; 329(19):1377-82. PubMed ID: 8413433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma.
    Smaldone MC; Jacobs BL; Smaldone AM; Hrebinko RL
    Urology; 2008 Sep; 72(3):613-6. PubMed ID: 18554696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of superficial bladder carcinoma: time to rethink the treatment strategies in the era of orthotopic neo-bladder.
    Singh PB; Kumar A; Das SK; Pandey AK; Sharma GK; Samir Swain HB; Trivedi S; Dwivedi US
    Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):881-5. PubMed ID: 20814125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods.
    Matsumoto K; Kikuchi E; Horiguchi Y; Tanaka N; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Urology; 2010 Jun; 75(6):1385-90. PubMed ID: 20110108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
    Herr HW; Dalbagni G
    BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.
    Hellenthal NJ; Ramirez ML; Evans CP; Devere White RW
    BJU Int; 2010 Feb; 105(4):485-8. PubMed ID: 19849694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
    Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
    Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined modality treatment with bladder preservation for muscle invasive bladder cancer.
    Sabaa MA; El-Gamal OM; Abo-Elenen M; Khanam A
    Urol Oncol; 2010; 28(1):14-20. PubMed ID: 18818110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of age and clinical factors in non-muscle-invasive bladder cancer treated with Bacillus Calmette Guerin therapy.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 May; 37(3):191-5. PubMed ID: 23634793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.